Sensitised patients | Nonsensitised patients | Significance between groups p-value | |||||
Baseline | 12 weeks | p-value | Baseline | 12 weeks | p-value | ||
Subjects n | 92 | 45 | |||||
ACQ score# | 3.1±1.1 | 1.7±1.2 | <0.001 | 3.3±1.0 | 1.8±1.0 | <0.001 | 0.795 |
AQLQ score¶ | 4.0±1.0 | 5.6±1.0 | <0.001 | 3.8±1.0 | 5.3±1.2 | <0.001 | 0.939 |
SNOT-20 score+ | 2.2±0.8 | 1.5±0.9 | <0.001 | 2.2±0.8 | 1.7±1.1 | <0.001 | 0.184 |
Patients taking OCS | 45 (49) | 27 (29) | <0.001 | 25 (56) | 14 (31) | <0.001 | 0.515 |
OCS mg·day−1 | 0 (0–110) | 0 (0–40) | <0.001 | 5 (0–75) | 0 (0–40) | <0.001 | 0.568 |
ICS μg·day−1 | 1600 (200–8000) | 1600 (0–8000) | 0.295 | 1600 (0–7400) | 1600 (0–8000) | 0.136 | 0.620 |
FEV1 % pred | 86.9±22.0 | 93±20.7 | <0.001 | 88.6±26.1 | 94.4±23.5 | 0.019 | 0.87 |
6MWD | 514±182 | 639±220 | <0.001 | 397±164 | 544±174 | <0.001 | 0.429 |
Total IgE kU·L−1 | 369 (7–5000) | 224 (6–4682) | 0.000 | 51 (5–765) | 40 (5–283) | 0.550 | 0.044 |
Blood eosinophils per μL of blood | 250 (0–1050) | 220 (50–570) | 0.022 | 120 (10–560) | 130 (80–630) | 0.037 | 0.005 |
FeNO ppb | 27 (5–224) | 18 (1–70) | <0.001 | 15 (5–75) | 16 (6–52) | 0.343 | 0.009 |
Data are presented as mean±sd, n (%) or median (range), unless otherwise stated. Total immunoglobulin (Ig)E and blood eosinophils at 12 weeks were measured only in 59 sensitised and 20 nonsensitised patients. ACQ: Asthma Control Questionnaire score; AQLQ: Asthma Quality of Life Questionnaire score; SNOT-20: Sino-Nasal Outcome Test; OCS: oral corticosteroids; ICS: inhalation corticosteroids; FEV1: forced expiratory volume in 1 s; % pred: % predicted; 6MWD: 6-min walking distance; FeNO: exhaled nitric oxide fraction. #: 0–6, where 0=well controlled; ¶: 1–7, where 7=best quality of life; +: 0–5, where 0=no complaints.